TFF PHARMACEUTICALS, INC.
FACT SHEET

Enabling Drug Delivery Therapies with Powerful Inhalable Solutions

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing new inhalation drug products for the treatment of chronic respiratory diseases and lung conditions, and partnering next-generation, direct-to-lung drug delivery options for a wide variety of therapeutics.

TFF Pharmaceuticals’ Thin Film Freezing Platform Addresses Current Drug Delivery Limitations:

- The company’s proprietary Thin Film Freezing (TFF) platform addresses an important drug delivery limitation: that of poor water solubility and absorption. In early testing, this proprietary platform has significantly improved the solubility of drugs that are poorly water-soluble, a class of drugs that comprise approximately one-third of the WHO Essential Drugs list and an estimated 40 percent of all New Chemical Entities. This would mean that the platform can make those drugs inhalable, which would improve their pharmacokinetic effect and minimize systemic side effects.

- In the case of some new drugs that cannot be developed due to poor water-solubility, the TFF platform has the potential to improve the pharmacokinetic effect of the drug to a level allowing for their development and commercialization.

- TFF Pharmaceuticals has generated enhanced performance formulations for dry powder delivery to the lungs, designed to treat pulmonary diseases and conditions such as Asthma, COPD, Invasive Pulmonary Aspergillosis (IPA), Allergic Bronchial Pulmonary Aspergillosis and Lung Transplants.

- The TFF dry powder drug formulations for inhalation of both biologic and small molecule drugs cannot currently be formulated for dry powder delivery by other means. TFF Pharmaceuticals expects its dry powder formulations, which can be delivered directly to the lungs via inhaler, will minimize certain negative side effects that result from delivering these drugs systematically.
Product Pipeline:

- The Company’s initial development focus is on TFF Vori and TFF Tac-Lac.

- TFF VORI is an inhaled dry powder drug intended to treat Invasive Pulmonary Aspergillosis (IPA), a severe fungal pulmonary disease with a mortality rate that can reach 90 percent in some patient populations. Early testing confirms the TFF platform can be used to formulate a dry powder version of Voriconazole, an off-patent drug generally considered to be the best antifungal drug for treating IPA. TFF Pharmaceuticals’ dry powder formulation directly targets the site of the fungal infection in the lung and could help reduce or eliminate the potentially fatal side effects associated with Voriconazole.

- TFF Tac-Lac is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine. Tacrolimus is currently the second most commonly administered immunosuppressive drug used in solid organ transplants, despite many challenges for patients and physicians when used for extended periods. TFF Pharmaceuticals’ dry powder version would provide a high drug concentration at the local site of action, with reduced side effects associated with oral dosage, potentially giving the Company a competitive advantage in the immunosuppressant market.

- Additional pipeline assets in early development include potential collaborations with large pharma partners, including 18 already identified candidates.

Robust Intellectual Property Portfolio:

- The scope of TFF Pharmaceuticals IP protection includes 39 patents issued and/or pending in the U.S. and internationally.

TFF Pharmaceuticals’ President and CEO: Glenn Mattes
NASDAQ: TFFP

Headquarters: Austin, Texas
Website: https://tffpharma.com

Company Contact:
Glenn Mattes
gmattes@tffpharma.com
215-880-2632

Investor and Media Relations Contact:
Paul Sagan
psagan@lavoiehealthscience.com
617-953-4779